Almost nine in ten U.S. adults meet criteria for at least an early stage of cardiovascular-kidney-metabolic syndrome, a cluster of interlocking risks that often progress quietly until a major event, according to new summaries from health groups and recent research.
The finding underscores a shift in how doctors describe overlapping threats from high blood pressure, abnormal cholesterol and blood sugar, excess weight, and reduced kidney function. Rather than treating these problems one by one, the American Heart Association has labeled their interaction as a single syndrome to flag danger sooner and steer patients into comprehensive care. Researchers say a large share of adults fall into stage 1 or 2, where signs may be subtle, while about one in six are already in advanced stages tied to heart attack, stroke and kidney disease. Advocates say awareness remains low even as the scope widens.
In recent analyses of national health data collected over the past decade, investigators reported that nearly 90% of adults qualified for stage 1 or higher, with men, older adults and Black Americans more likely to appear in advanced stages. Younger people are not exempt: more than 80% of young and middle-aged adults show early risk, according to summaries shared alongside the new push for unified screening. Eduardo Sanchez, the American Heart Association’s chief medical officer for prevention, said the point is to connect the dots that patients live with every day. “It’s really common to have heart, kidney and metabolic risk factors at the same time,” Sanchez said, adding that many people still view each issue in isolation.
CKM syndrome is not a single illness. It is a staging framework that groups related conditions because they feed each other and worsen outcomes when combined. Stage 0 indicates no evident risk; stage 1 flags early metabolic changes such as elevated body mass index or prediabetes; stage 2 adds multiple risk factors like hypertension and abnormal lipids; stage 3 adds kidney impairment or clearly diagnosable metabolic disease; and stage 4 marks overt cardiovascular disease. In practice, the label is meant to trigger coordinated care across cardiology, nephrology and metabolic medicine, including tracking blood pressure, A1C, lipids and kidney markers together over time. The model also reflects recent mortality data showing that intertwined heart, kidney and metabolic problems remain the nation’s top killers.
The advisory reclassifying these risks appeared in 2023 and has since been paired with public-awareness efforts. A national survey last fall found that roughly nine in ten adults had not heard of CKM syndrome by name, even though the vast majority had at least one risk factor. In that poll, most respondents said they wanted to know how the syndrome is diagnosed and treated and whether combined care could improve outcomes. The association said it plans to release clinical guidance this year to help clinicians stage patients consistently and refer them for integrated care pathways when multiple risks travel together.
While the prevalence numbers are alarming, scientists emphasize they reflect a broad net that catches early signals as well as advanced disease. In many cases, stage 1 or 2 may be reversible if addressed, clinicians say, particularly when weight, blood pressure and glucose are drifting upward together. Researchers analyzing older federal health surveys found little improvement across the past decade in the proportion of adults who qualify for CKM stages, a trend they attribute to mixed progress: some measures improved while others worsened, leaving overall risk stubbornly high. The share in the most advanced stage remains smaller but significant, and it drives the heaviest burden of heart attack, heart failure and stroke.
For now, officials caution that public understanding of the staging system lags behind its adoption in clinics. Many patients are still told they have “borderline” blood pressure or “slightly high” blood sugar without a clear sense of how those numbers interact. Health leaders argue that the CKM framework makes the stakes explicit by treating early signals as part of a connected pathway rather than a set of isolated readings. It is also intended to reduce gaps in care that appear when a person sees multiple specialists who lack a shared plan. The association has stood up a CKM Health Initiative to align screening tools, registries and care teams as more systems test the approach.
The stage labels arrive as heart disease and stroke continue to account for more deaths than any other cause in the United States. Officials note that progress against cardiovascular mortality slowed during the pandemic years and has not fully returned to prior trends. Within that backdrop, kidney disease and metabolic disorders—including type 2 diabetes and severe obesity—have risen in tandem, and researchers say the biology links all three: high blood sugar and blood pressure damage vessels; injured kidneys, in turn, amplify blood pressure swings and inflammatory signals; and excess visceral fat drives hormonal changes that worsen both. The cycle can be quiet until a crisis lands in an emergency room.
Clinicians say the practical questions now are procedural. Hospitals and primary-care groups are deciding how to add staging to routine checkups, whom to screen for kidney markers earlier, and how to share responsibility among cardiology, nephrology and endocrinology once a patient crosses into stage 3 or 4. Insurers are weighing coverage for team-based visits and case management. Public-health agencies are drafting plain-language explanations so patients recognize that “normal” readings can stack up into risk when combined. Specialists are also debating thresholds for staging in adolescents and young adults as pediatric obesity and prediabetes rise.
The research underpinning the 90% figure draws on long-running federal health surveys that collect physical exams and blood tests from nationally representative samples. Analysts applied the new staging rules to older data sets to estimate how many adults today would qualify for each stage. They report wide disparities: advanced stages cluster in older adults, men and Black Americans, reflecting long-known gaps in hypertension control, cholesterol management and access to preventive care. Geographic differences appear as well, with higher-risk clusters in parts of the South and Midwest. Scientists caution that because definitions are new, estimates may shift as criteria are refined and as more recent data sets come online.
Despite those caveats, the framing has moved quickly through conferences and hospital committees because it matches what clinicians see in practice. A patient with slightly elevated blood pressure, midline weight gain and borderline A1C often bounces among offices without a shared plan; under CKM staging, that person lands on a track where blood pressure targets, lipid goals, glucose control and early kidney checks are handled together. “The heart, kidney and metabolic systems are connected and should be treated in a coordinated way,” Sanchez said in announcing the awareness campaign, describing the new effort to move patients earlier onto comprehensive pathways.
Public-health leaders say the next steps include releasing formal guidance on CKM staging and care, building registries that track how patients move between stages, and measuring whether coordinated care reduces hospitalizations and deaths. Researchers are also studying how new medicines—including drugs that reduce cardiovascular events in diabetes and protect kidney function—might be deployed earlier for people in stage 2 or 3. Health systems are testing bundled visits that pair primary care with pharmacy consultations, nutrition counseling and remote blood pressure checks to close gaps that emerge between annual physicals.
Questions remain. Because CKM syndrome groups multiple conditions, it can be challenging to explain to patients who are used to hearing single-diagnosis labels. Some clinicians worry that a broad label could overwhelm patients or lead to overtesting without clear action plans. Others argue the opposite: without a unifying term, patients underestimate risk and drift through years of borderline results. The association says the 2026 guidance will include plain-language staging descriptions, example care pathways and quality metrics so systems can evaluate whether the new approach improves outcomes and equity.
As of Wednesday, health officials said work on the first dedicated CKM guidance is in its final stages, with publication expected this year. Advocacy groups plan additional outreach to explain how heart, kidney and metabolic health interact across a lifetime. Researchers say the most immediate benchmark will be whether awareness—among both clinicians and the public—catches up with the scope of the problem as newly staged patients move into coordinated care.
Author note: Last updated January 21, 2026.